Cempra Pharmaceuticals, Inc.'s Solithromycin Demonstrates Therapeutic Potential Beyond Anti-Bacterial Activity
4/4/2014 7:45:01 AM
CHAPEL HILL, N.C., April 3, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced the presentation of a late-breaking abstract entitled "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," at 9:15 a.m. EDT, May 6, at Digestive Disease Week (DDW®) 2014 in Room S105A at McCormick Place in Chicago. The presentation will be included in the session entitled "Basic Late Breaking Abstract Session."
Help employers find you! Check out all the jobs and post your resume.
comments powered by